vaccine, increased the risk of encephalitis most likely because of autoimmune pro-inflammatory 23 T helper 1 (Th1) response against all forms of Aβ. Immunization against less abundant but 24 potentially more pathologically relevant Aβ products, such as N-terminally-truncated 25 pyroglutamate-3 Aβ (AβpE3), could provide efficacy and improve tolerability in Aβ 26 immunotherapy. Here, we describe a selective vaccine against AβpE3 using the diphtheria toxin 27 mutant CRM197 as carrier protein for epitope presentation. CRM197 is currently used in 28 licensed vaccines and has demonstrated excellent immunogenicity and safety in humans. In 29 mice, our AβpE3:CRM197 vaccine triggered the production of specific anti-AβpE3 antibodies 30 that did not cross-react with Aβ1-42, non-cyclized AβE3, or N-terminally-truncated 31 pyroglutamate-11 Aβ (AβpE11). AβpE3:CRM197 antiserum strongly labeled AβpE3 in 32 insoluble protein extracts and decorated cortical amyloid plaques in human AD brains. Anti-33
AβpE3 antibodies were almost exclusively of the IgG1 isotype, suggesting an anti-inflammatory 34
Th2 response bias to the AβpE3:CRM197 vaccine. To the best of our knowledge, this study 35
shows for the first time that CRM197 has potential as a safe and suitable vaccine carrier for 36 active and selective immunization against specific protein sequence modifications or 37 conformations, such as AβpE3. 38
INTRODUCTION 43
Anti-amyloid-β (Aβ) immunotherapy is under intense investigation in Alzheimer's disease (AD) 44 (Lemere 2013; Wisniewski & Goñi 2015) . Aβ is the core component of the amyloid plaques, a 45 hallmark of the AD brain, and mutations in its precursor APP or in presenilins-the catalytic 46 components of the Aβ-producing enzyme γ -secretase-cause familial AD (Checler 1995; 47 3 cerebral accumulation might interfere with AD pathogenesis (Citron 2010) . Aβ immunization 49 has proven to be very effective at promoting Aβ clearance, at least in animal models. Preclinical 50 and clinical studies, however, have been hampered by unforeseen side effects. The first clinical 51 trial AN-1792, which evaluated an Aβ1-42/QS21 vaccine, was halted in phase II when about 6% 52 of the patients developed meningoencephalitis (Holmes et al. 2008) . Although the exact 53 mechanism that led to acute brain inflammation in this clinical trial remains unclear, it is 54 believed that encephalitis arose from an autoimmune reaction triggered by a vaccine directed 55 against the abundant self-protein Aβ coupled to the strong adjuvant QS21, thus favoring pro-56 inflammatory T helper 1 (Th1) immune responses (Tabira 2010) . In this context, second 57 generation anti-Aβ vaccines were designed to prevent T-cell responses during anti-Aβ 58 immunization. These vaccines tested, for instance, N-terminal epitopes within the Aβ sequence 59 and adjuvants that minimize T-cell engagement and favor B-cell responses (Wisniewski & Goñi 60 2015) . Another approach is passive immunization, which has the advantage to bypass T-cell 61 engagement and allow a better control of monoclonal antibody (mAb) dosage and epitope 62 targeting. However, recent phase III AD trials of two anti-Aβ mAb, solanezumab and 63 bapineuzumab, failed to slow cognitive or functional decline in patients with mild-to-moderate 64 AD (Hampel et al. 2015) . The main argument put forward to explain the lack of efficacy of these 65 passive immunization approaches was that treatment might have started too late to reverse or 66 delay the disease process (Karran & Hardy 2014) . It is also possible that passive immunization 67 might not deliver enough mAb to promote plaque clearance. Passive immunization also raised 68 concerned because of the practical and financial sustainability of injecting and monitoring mAb 69 injections on a regular basis for several years (Golde 2014) . 70
In the amyloidogenic pathway, APP is sequentially endoproteolyzed by the proteases β-71 secretase/BACE1 and the presenilin/γ-secretase complex to produce various Aβ peptides, 72
including the most abundant isoforms Aβ1-40 and Aβ1-42 (De Strooper et al. 2010 ). In addition 73 to these major Aβ isoforms, N-terminally truncated Aβ products have been identified in the AD 74 brain, including peptides starting with pyroglutamate residues at the position 3 (AβpE3) and 11 75 2013), we speculated that CRM197 could be conjugated to minimal peptide epitopes to facilitate 96 the generation of conformation/modification-specific antibodies directed against pyroglutamate 97
Aβ. We show that our vaccines in mice-composed of AβpE3-8 or AβpE11-16 peptides 98 covalently conjugated to CRM197-triggered the production of fully specific antibodies directed 99 against AβpE3 and AβpE11, respectively. Anti-AβpE3 antibodies stained brains from AD 100 patients by western blotting (WB) and immunohistochemistry (IHC), and were almost 101 exclusively of the IgG1 isotype, indicating the engagement of a Th2 response. Labs) was reconstituted with PBS/EDTA to obtain a 2 mg/mL solution. To irreversibly crosslink 112 the peptides to the carrier protein, CRM197 was first activated with a 20-fold molar excess of 113 succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) crosslinker (Pierce, at 114 1.5 mg/mL in DMSO). After a 30 min incubation at room temperature (RT), the 115 SMCC/CRM197 mixture was desalted on a resin column (Zeba Desalt Spin Column, Pierce). 116
Activated CRM197 was then combined with AβpE3-8 and AβpE11-16 peptide solutions and 117 incubated for 30 min at RT. A ratio of 1:10 (CRM197 to peptides) was empirically chosen. 118 
ELISA for measurement of antibody responses 130
Anti-AβpE3-8, anti-AβpE11-16, and anti-CRM197 antibody levels in mouse serum were 131 determined by enzyme-linked immunosorbent assay (ELISA). 96-well plates (Maxisorp, Nunc) 132
were coated with 100 μL of 2 μg/mL AβpE3-8, AβpE11-16, or CRM197 in carbonate buffer 133 (0.05 M, pH 9.6) and incubated overnight at 4 o C. The following morning, plates were blocked 134 for 1 h at RT with 5% skim milk in TBS containing 0.05% Tween 20 (TBST). After washing 135 with TBST, serial dilutions of individual mouse serum samples (diluted in PBST containing 1% 136 skim milk) were prepared and 100 μL/well of mouse serum was incubated for 2 h at RT. After 5 137 more washes, 100 μL/well horseradish peroxidase (HRP)-conjugated goat anti-mouse 138 immunoglobins (Igs) secondary antibody (Southern Biotech, diluted 1:500 in PBST containing 139 1% skim milk) was incubated for 1 h at RT. TMB substrate was added after another wash and 140 the reaction was allowed to develop for 30 min at RT. The optical density was measured at 405 141 6 nm using a TECAN GENios Pro plate reader. Antibody responses were expressed as titers. 142
Antibody titers were determined via a linear fit for optical density values of 9 dilutions, and 143 expressed in arbitrary units by calculating the reciprocal dilution that gave 50% of the maximum 144 absorbance response. For measurement of Ig isotype specificity (IgG1, IgG2b, IgG2c, IgG3, IgA, 145
and IgM), an ELISA protocol similar to that described above was followed. Briefly, ELISA 146 plates were coated as described above. Reference mouse IgG1, IgG2b, IgG2c, IgG3, IgA and 147
IgM antibodies were diluted in TBST containing 1% skim milk. To detect specific binding, 148
HRP-conjugated anti-mouse IgG1, IgG2b, IgG2c, IgG3, IgA and IgM antibodies (Southern 149 Biotech) were used at a dilution of 1:500, TMB was then added as described above. The 150 presence of antigen-specific isotype-specific antibodies was detected and measured as described 
Human cases and brain protein extraction 159
Cases were obtained from the Albert Einstein College of Medicine human brain bank, Bronx, 160 NY (see Table) . Brain samples (see Table) were processed as previously described (Vingtdeux et Protein extracts from SDS and FA fractions obtained from human brain samples were analyzed 170 by SDS-PAGE using the indicated antibodies. Samples were electrophoresed on 10% Tris-HCl 171 gels (phospho-tau and actin analysis) or on 16.5% Tris-Tricine gels (Aβ isoforms, Biorad) and 7 transferred onto nitrocellulose membranes. Aβ was detected as previously described (Vingtdeux 173 et al. 2015) . Briefly, membranes were microwaved for 5 min in PBS. Membranes were then 174 blocked in 5% fat-free milk in TBS, and incubated with primary antibodies overnight at 4°C. A 175 standard ECL detection procedure was then used. 176 177
Immunohistochemistry (IHC) 178
Five-μm-thick sections of formalin-fixed paraffin-embedded brain tissue were immunostained 179 with 6E10 mAb (Covance, 1:1000 dilution) or AβpE3:CRM197 antiserum (1:2 dilution). 
Immunogenicity of CRM197 in mice 199
We first verified that unconjugated CRM197 without adjuvant was immunogenic in C57BL/6J Day 30 (Fig. 1A) . Saline control injections as expected did not elicit an anti-CRM197 antibody 205 response (Fig. 1A) . Ig isotype determination revealed that anti-CRM197 antibodies were 206 exclusively of the IgG1 isotype and reached levels of ~35 μg/mL at Day 30 post-prime injection 207 ( Fig. 1B) . 208 209
Immunogenicity of the AβpE3:CRM197 and AβpE11:CRM197 conjugate vaccines 210
A short peptide sequence of 6 residues starting at pE3 (pE3-8) or pE11 (pE11-16) linked in C-211 terminal to a 3-residue spacer (see Methods) was chosen to facilitate the production of 212 conformation/modification-specific antibodies directed against Aβ. A 6-residue peptide epitope 213 has also the advantage to be shorter than conventional T-cell epitopes and thus might prevent 214
unwanted T-cell activation and detrimental pro-inflammatory responses (Rammensee 1995) . Injection of free AβpE3-8 and AβpE11-16 peptides (unconjugated to CRM197) did not elicit 225 immunogenic responses against these peptides (Figs. 2B and 2D) . 226
As observed for the immunogenic responses to unconjugated CRM197 (Fig. 1) , the anti-227 The AβpE3:CRM197 vaccine produces antibodies that react with amyloid deposits in AD 234 brains 235
Antiserum produced after immunization with the AβpE3:CRM197 vaccine labeled synthetic 236 AβpE3-42 peptide by WB (Fig. 4A) . Importantly, AβpE3:CRM197 antiserum did not cross-react 237 with synthetic AβpE11-42 or synthetic Aβ1-42 ( Fig. 4A) , showing that the antibodies produced 238 did not recognize non-specifically the pE modification nor they interacted with an internal 239 epitope containing residues 3-8 of Aβ1-42. AβpE3:CRM197 antiserum is thus fully specific to 240
AβpE3. Strikingly, AβpE3:CRM197 antiserum was also able to label AβpE3 in 241 insoluble/aggregated brain protein preparations (FA fractions, see Methods) obtained from 6 242 independent well-characterized AD patients (see Table) . Almost no immunoreactivity was 243 observed in the corresponding soluble preparations (SDS fractions) ( Fig. 4B) , indicating that the 244 anti-AβpE3 antibodies produced by the AβpE3:CRM197 vaccine recognize human amyloid 245 material in the AD brain, and that AβpE3 is mostly aggregated. Of note, AβpE3 246 immunoreactivity was also observed in normal control brains that contained large amounts of 247 aggregated total Aβ (also detected with 6E10 mAb in the insoluble fractions) (Fig. 4B) . In fact, a 248 strong parallel was observed between the levels of aggregated total Aβ and aggregated AβpE3 in 249 brains from both normal and AD individuals (Fig. 4B ), suggesting that AβpE3 is a marker for 250 amyloid deposition but is not specific to AD. 251
In addition, AβpE3:CRM197 antiserum decorated amyloid plaques in human AD brain 252 slices by IHC. Most of the anti-AβpE3 immunoreactivity was observed on plaques present in the 253 cortex (entorhinal and parahippocampal cortices, Fig. 4C ). Although amyloid plaque deposition 254 was very pronounced in the AD case analyzed, only a few plaques were labeled with the 255 AβpE3:CRM197 antiserum in the hippocampal formation (the dentate gyrus, CA1, and 256 subiculum, Fig.4C ). Interestingly, in adjacent sections of the parahippocampal cortex, identical 257 plaques stained for both total Aβ (6E10 mAb) and AβpE3 (Fig. 4C, arrows) . This co-staining 258 revealed that anti-AβpE3 antiserum preferentially decorated highly dense plaques. Of note, anti-259 In this study, we show that minimal epitopes can be designed to generate vaccines that are fully 266 specific to the pyroglutamate modifications of Aβ. Indeed, antiserum obtained after 267 immunization with the AβpE3:CRM197 conjugate vaccine, demonstrated excellent 268 immunoreactivity against synthetic and AD brain-derived AβpE3, with no detectable cross-269 reactivity with Aβ1-42, non-cyclized AβE3, or AβpE11. Further analysis using AD brain 270 samples revealed that AβpE3:CRM197 antiserum mainly decorated highly aggregated amyloid 271 material, supporting the notion that AβpE3 is associated with the dense core of the senile plaques 272 Our study strengthens the notion that CRM197 has strong potential for 281 peptide presentation. This work further demonstrates that CRM197 might particularly be useful 282 for the generation of conformation/modification-specific anti-peptide vaccines. 283
Both active and passive immunization directed against Aβ have their respective pros and 284 cons (see Introduction) and there is no consensus yet as to whether one approach has a stronger 285 therapeutic potential for AD. Both approaches-targeting different Aβ epitopes-are therefore 286 actively investigated at the pre-clinical and clinical levels. Our approach was aimed at increasing 287 the anti-Aβ immunotherapy toolkit by proposing an active immunization strategy specifically 288 targeting N-terminally-truncated pyroglutamate Aβ. Further studies will be required to validate 289 the utility of such a vaccine in AD mouse models of amyloid deposition. It should be noted, 290 however, that several studies using passive immunization specifically targeting AβpE3 have 291 already been conducted in different mouse amyloid models. These studies provided solid and AβpE3 immunization could also reduce the pathology in these models. 296
In this context, new immunization formulations for the AβpE3:CRM197 vaccine will 297 have to be tested to boost antibody production. Indeed, although the AβpE3:CRM197 antiserum 298 was able to react with both synthetic AβpE3 and AD-brain derived amyloid material, its 299 antibody levels in the serum around 1.5 μg/mL are likely to be too low to allow clearance of 300
AβpE3 and amyloid in mouse AD models. Thus, future experiments will also have to determine 301 whether immunogenicity of the AβpE3:CRM197 vaccine can be improved by repeated injections 302
and/or addition of adjuvants. Interestingly, recent data demonstrated that combined addition of 303 the adjuvants aluminum hydroxide and CpG can increase more than 100-fold the antibody titer In conclusion, we propose that conjugation of peptides AβpE3-8 and AβpE11-16 to 308 CRM197 can generate fully specific vaccines directed against AβpE3 and AβpE11, respectively. 309
The main strength of this immunization strategy is to combine the advantages of a vaccine with 310 the high specificity of targeting particularly amyloidogenic and neurotoxic sub-species of Aβ, 311 while sparing the more abundant and maybe more physiologically relevant full-length Aβ40 and 312
Aβ42. Coomassie blue staining of CRM197 alone or conjugated to AβpE3-9 (AβpE3-9:CRM197) or 535
AβpE11-16 (AβpE11-16:CRM197) (A). Anti-AβpE3-9 (B), anti-Aβ3-9 (C), anti-AβpE11-16 536 (D), and anti-Aβ11-16 (E) Ig titers in sera obtained from mice immunized with AβpE3-9 or 537
